within Pharmacolibrary.Drugs.S_SensoryOrgans.S02A_Antiinfectives.S02AA18_Cefmenoxime;

model Cefmenoxime
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.8055555555555557e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0101,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0064,
    k12 = 3.6666666666666666e-06,
    k21 = 3.6666666666666666e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefmenoxime</td></tr><tr><td>ATC code:</td><td>S02AA18</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefmenoxime is a third-generation cephalosporin antibiotic used for the treatment of a variety of bacterial infections, particularly those caused by Gram-negative organisms. It has been primarily used in Japan and some other countries, but it is not widely approved or used in the United States or Europe today.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters for healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S02AA18 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefmenoxime;
